Judith A. Salerno, MD, MS, has been named president and CEO of the breast cancer research and advocacy group Susan G. Komen for the Cure in Dallas, TX, beginning in September. She succeeds the group's founder, Nancy G. Brinker, who will assume a new role focusing on Komen's global strategy and development.
Salerno is currently the executive director and chief operating officer of the Institute of Medicine (IOM) of the National Academy of Sciences. In that role, she has directed research and policy programs and has overseen the National Cancer Policy Forum, a consortium of government, industry, academic, and consumer representatives that examines emerging high-priority policy issues in cancer.
Prior to joining the IOM, Salerno was deputy director of the National Institute on Aging at the NIH. Board-certified in internal medicine, she has also directed geriatrics and extended care programs for the U.S. Department of Veterans Affairs.
Michael Stratton, MD, PhD, director of the Wellcome Trust Sanger Institute in Hinxton, UK, has been awarded a knighthood by Queen Elizabeth II in recognition of his outstanding scientific achievements.
Stratton has led international efforts to understand the genetic changes that cause cancer. In his early work, he discovered BRCA2, a hereditary breast cancer susceptibility gene. Subsequently, he founded the Cancer Genome Project at the Sanger Institute, and he directed the team that discovered mutations in the BRAF gene in malignant melanoma, which has led to new treatments for this disease. He continues to study the mutational processes that lead to the development of cancer.
For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.
